Here is a weekly snapshot from the Gov of Can.
Vaccine Surveillance Report - Adverse Events following Immunization
Info
Update: December 24, 2009
Quote:
Weekly Snapshot
As of December 12, 2009, 24.071 million doses of three types of vaccine had been distributed across Canada:
Arepanrix (adjuvanted H1N1 flu vaccine from GlaxoSmithKline)
Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant from GlaxoSmithKline)
Panvax (unadjuvanted H1N1 flu vaccine from CSL Australia)
Since the start of the H1N1 flu vaccine campaign through December 12, a total of 4,995 adverse events have been reported to provincial and territorial immunization programs of which 155 met one or more of the criteria to be considered serious. Ninety-four cases of anaphylaxis are included among the serious adverse events.
The reporting rate of adverse events per 100,000 doses distributed is 20.8. The reporting rate of serious adverse events is 0.64 per 100,000 doses distributed. To date, the overall frequency of anaphylaxis following H1N1 immunization is 0.39 per 100,000 doses distributed, which does not exceed the normal range observed after receiving any vaccine.
Analysis
. Six deaths have been reported to date and are under investigation.
There have been 8 cases of Guillain-Barre Syndrome (GBS) reported to date (0.3 per million doses distributed) following vaccination. The 6 cases reported following vaccination with the H1N1 vaccine are still under investigation.
GBS is an acute illness characterized by sudden onset of weakness or paralysis (see Guillain-Barre Syndrome Frequently Asked Questions).
|
http://www.phac-aspc.gc.ca/alert-ale...addeve-eng.php
I wonder is there a difference between distributed and administered....